{
    "clinical_study": {
        "@rank": "95823", 
        "brief_summary": {
            "textblock": "The primary objective of this study is to assess the extent to which the Prosigna\u2122 Breast\n      Cancer Prognostic Gene Signature Assay affects the medical oncologist's treatment\n      recommendations regarding adjuvant chemotherapy and actual treatments received for patients\n      with early-stage breast cancer. Changes in treatment recommendations will include (1)\n      hormonal therapy alone, (2) hormonal therapy plus chemotherapy, and (3) changes in types of\n      chemotherapy if chemotherapy was recommended before and after the test"
        }, 
        "brief_title": "A Prospective Observational Study of Clinical Outcomes for the NanoString\u00ae Technologies, Inc. Prosigna\u2122 Gene Signature Assay", 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Resected node-negative, estrogen-receptor-positive, HER2-negative early- stage\n             invasive breast cancer (T1-T2, N0, pN0 (i+), pN0 (mol+), M0)\n\n               -  Estrogen receptor status will be evaluated by Immunohistochemistry (IHC) and\n                  more than 1% of stained tumor cells will be considered positive.\n\n               -  HER2 status will be evaluated by IHC (0 or 1+, or 2+ will be considered\n                  negative) and by in-situ fluorescence hybridization.\n\n          -  Postmenopausal women defined as:\n\n               -  Natural Amenorrhea > 12 months, regardless of age\n\n               -  Bilateral oophorectomy, regardless of age (the oophorectomy must have been\n                  carried out at least 4 weeks before entering the study)\n\n               -  Radiological castration with amenorrhea > 3 months, regardless of age\n\n               -  Hysterectomy and postmenopausal blood levels\n\n          -  Able to give consent\n\n          -  Eligible for treatment of breast cancer with adjuvant chemotherapy\n\n          -  ECOG performance status of 0 or 1\n\n        Exclusion Criteria:\n\n          -  Tumor size T3-T4\n\n          -  Non-invasive breast cancer (e.g., Paget's disease, DCIS)\n\n          -  Tumors with nodes that are not N0, pN0 (i+), or pN0 (mol+)\n\n          -  Tumors that are estrogen-receptor negative or HER2 positive\n\n          -  Have metastatic disease\n\n          -  Unable to give informed consent\n\n          -  Unable to complete patient reported outcome surveys\n\n          -  Have contraindications for adjuvant chemotherapy\n\n               -  Age, performance status, significant comorbidities\n\n          -  ECOG performance status > 1"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Postmenopausal women with node-negative, estrogen-receptor positive, HER2-negative\n        early-stage breast cancer. Investigators will offer enrollment to consecutively seen women\n        who meet the entry criteria."
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01974856", 
            "org_study_id": "PTL-00172"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 28, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "PD Dr. Christian Schem", 
                    "phone": "0049 431 597-0"
                }, 
                "facility": {
                    "address": {
                        "city": "Kiel", 
                        "country": "Germany", 
                        "zip": "24105"
                    }, 
                    "name": "Universit\u00e4tsklinikum Kiel"
                }, 
                "investigator": {
                    "last_name": "PD Dr. Christian Schem", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Prof Wolfgang Janni", 
                    "phone": "0731 / 500-58501"
                }, 
                "facility": {
                    "address": {
                        "city": "Ulm", 
                        "country": "Germany", 
                        "zip": "89081"
                    }, 
                    "name": "Universit\u00e4tsfrauenklinik Ulm"
                }, 
                "investigator": {
                    "last_name": "Prof Wolfgang Janni", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Prospective Observational Study of Clinical Outcomes for the NanoString\u00ae Technologies, Inc. Breast Cancer Intrinsic Subtype Test", 
        "overall_official": {
            "affiliation": "Leitung des Brustzentrums der Universit\u00e4t M\u00fcnchen", 
            "last_name": "Nadia Harbeck, Prof. Dr. med", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The proportion of patients whose choice of treatment is changed as a result of receiving the Prosigna test result.", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01974856"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "NanoString Technologies, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "NanoString Technologies, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}